Galectin 3 complements BNP in risk stratification in acute heart failure BIOMARKERS Fermann, G. J., Lindsell, C. J., Storrow, A. B., Hart, K., Sperling, M., Roll, S., Weintraub, N. L., Miller, K. F., Maron, D. J., Naftilan, A. J., McPherson, J. A., Sawyer, D. B., Christenson, R., Collins, S. P. 2012; 17 (8): 706-713


Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure.Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial.Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide.In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

View details for DOI 10.3109/1354750X.2012.719037

View details for Web of Science ID 000311681100003

View details for PubMedID 22998064